Enjoy complimentary customisation on priority with our Enterprise License!
The lateral epicondylitis treatment market share is expected to increase by USD 1.91 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 4%.
This lateral epicondylitis treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers market segmentations by type (Non-surgical treatment and Surgical treatment) and geography (North America, Europe, Asia, and ROW). The lateral epicondylitis treatment market report also offers information on several market vendors, including 3M Co., Bayer AG, Cipla Inc., Colfax Corp., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Perrigo Co. Plc, Pfizer Inc., and Sun Pharmaceutical Industries Ltd. among others.
Download the Free Report Sample to Unlock the Lateral Epicondylitis Treatment Market Size for the Forecast Period and Other Important Statistics
Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The rising awareness about lateral epicondylitis is notably driving the lateral epicondylitis treatment market growth, although factors such as lack of approved treatment may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the lateral epicondylitis treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Driver for the Lateral Epicondylitis Treatment Market
Rising awareness about lateral epicondylitis is one of the key drivers for the market in focus. Lateral epicondylitis is common in people who participate in physical activities. Moreover, it can also occur in people who apply more pressure on the extensor carpi radialis brevis and longus muscles of the forearm. These people observe severe and long-term pain around the elbow if the condition is left untreated. Hence, various government and non-government organizations are initiating certain programs to increase awareness among people and avoid delays in diagnosis. The increase in the number of organizations and institutes that raise awareness among people about lateral epicondylitis is expected to drive the growth of the global lateral epicondylitis treatment market during the forecast period.
Key Challenge for the Lateral Epicondylitis Treatment Market
Lack of approved treatment is a key challenge for the market in focus. Lateral epicondylitis is a common problem with many available treatment options, but the largely recommended treatment option is the combination of corticosteroids, physiotherapy, and bracing. The majority of patients benefit from this combination of treatment methods. However, there is no approved treatment for lateral epicondylitis. The lack of approved treatments in the market for lateral epicondylitis is expected to hamper the growth of the global lateral epicondylitis treatment market during the forecast period.
This lateral epicondylitis treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the lateral epicondylitis treatment market encompasses successful business strategies deployed by the key vendors. The lateral epicondylitis treatment market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The lateral epicondylitis treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
For more insights on the market share of various regions Request for a FREE sample now!
32% of the market's growth will originate from North America during the forecast period. The US is the key market for lateral epicondylitis treatment in North America. Market growth in this region will be slower than the growth of the market in other regions.
Rising awareness about lateral epicondylitis in the region will facilitate the lateral epicondylitis treatment market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
To gain further insights on the market contribution of various segments Request for a FREE sample
The lateral epicondylitis treatment market share growth by the non-surgical treatment segment will be significant during the forecast period. The non-surgical treatment for lateral epicondylitis includes corticosteroid injections, nonsteroidal anti-inflammatory drugs (NSAIDs), extracorporeal shock wave therapy, braces, and physical therapies. The growth of this segment is mainly attributed to the availability of injectable corticosteroid suspension, as adjunctive therapy for the treatment of epicondylitis.
This report provides an accurate prediction of the contribution of all the segments to the growth of the lateral epicondylitis treatment market size and actionable market insights on post COVID-19 impact on each segment.
Lateral Epicondylitis Treatment Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4% |
Market growth 2021-2025 |
$ 1.91 billion |
Market structure |
Fragmented |
YoY growth (%) |
3.49 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 32% |
Key consumer countries |
US, UK, Japan, Germany, and China |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
3M Co., Bayer AG, Cipla Inc., Colfax Corp., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Perrigo Co. Plc, Pfizer Inc., and Sun Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Type
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.